Abbott Laboratories (ABT)
ABT trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/0001628280-26-010185-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ABT on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000001800 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | IL |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $44.3B |
| Net income | $6.5B |
| Operating income | $8.1B |
| Net margin | 14.7% |
| Operating margin | 18.2% |
| Revenue growth | +5.7% |
| Cash | $8.5B |
| Total assets | $86.7B |
| P/E (computed) | 28.5× |
| P/S (computed) | 4.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $4.1B cash; operating cash flow $2.2B a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,731,941,601 (2026-09-30); 1,738,871,947 a year earlier; 1,736,058,536 three years earlier. | Cover page 2026-09-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-02-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Chicago, Illinois, United States | PCAOB Form AP 2026-03-11 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $4.4M, sold $47.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $13.0B | $920.0M | $1.7B | $4.1B | $31.2B | $48.2B | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $12.6B | $928.0M | $2.5B | $5.1B | $32.6B | $46.6B | 10-Q 2026-07-28 |
| Q1 2026 2026-03-31 | $11.2B | $1.1B | $1.3B | $6.8B | $34.0B | $45.1B | 10-Q 2026-04-29 |
| Q4 2025 2025-12-31 | $11.5B | $1.8B | $3.3B | $8.5B | $12.9B | $44.3B | 10-K 2026-02-20 |
| Q3 2025 2025-09-30 | $11.4B | $1.6B | $2.8B | $7.5B | $12.9B | $43.8B | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $11.1B | $1.8B | $2.0B | $7.0B | $13.4B | $43.1B | 10-Q 2026-07-28 |
| Q1 2025 2025-03-31 | $10.4B | $1.3B | $1.4B | $6.5B | $13.2B | $42.3B | 10-Q 2026-04-29 |
| Q4 2024 2024-12-31 | $11.0B | $9.2B | $2.9B | $7.6B | $14.1B | $42.0B | 10-K 2026-02-20 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-25 |
| Latest annual report | 10-K | 2026-02-20 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-03-13 |
Source: SEC EDGAR submissions feed, 1,002 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.3% |
| 1 month | +5.8% |
| 3 months | -2.5% |
| Year to date | -13.4% |
| 1 year | -16.0% |
| From 52-week high | -16.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVO | Novo Nordisk A/S | $41.60 | -0.07% | $184.2B |
| PFE | Pfizer Inc. | $28.86 | -0.10% | $164.5B |
| VRTX | Vertex Pharmaceuticals Incorporated | $537.79 | -0.15% | $136.4B |
| BMY | Bristol-Myers Squibb Company | $62.93 | -0.79% | $128.6B |
| AZN | AstraZeneca PLC | $184.02 | -0.23% | $285.4B |
| SNY | Sanofi ADS | $48.39 | +0.04% | $118.0B |
| NVS | Novartis AG | $160.20 | -0.19% | $305.7B |
| GSK | GSK plc | $50.41 | -0.08% | $102.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier